JPWO2020178721A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020178721A5 JPWO2020178721A5 JP2021551939A JP2021551939A JPWO2020178721A5 JP WO2020178721 A5 JPWO2020178721 A5 JP WO2020178721A5 JP 2021551939 A JP2021551939 A JP 2021551939A JP 2021551939 A JP2021551939 A JP 2021551939A JP WO2020178721 A5 JPWO2020178721 A5 JP WO2020178721A5
- Authority
- JP
- Japan
- Prior art keywords
- leucine
- pharmaceutically acceptable
- acceptable salt
- acetyl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024155453A JP2024170602A (ja) | 2019-03-02 | 2024-09-10 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812987P | 2019-03-02 | 2019-03-02 | |
| US62/812,987 | 2019-03-02 | ||
| US201962842296P | 2019-05-02 | 2019-05-02 | |
| US62/842,296 | 2019-05-02 | ||
| US201962888894P | 2019-08-19 | 2019-08-19 | |
| US62/888,894 | 2019-08-19 | ||
| US201962895144P | 2019-09-03 | 2019-09-03 | |
| US62/895,144 | 2019-09-03 | ||
| PCT/IB2020/051767 WO2020178721A1 (en) | 2019-03-02 | 2020-03-02 | Leucine, acetyl leucine, and related analogs for treating disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155453A Division JP2024170602A (ja) | 2019-03-02 | 2024-09-10 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022522819A JP2022522819A (ja) | 2022-04-20 |
| JPWO2020178721A5 true JPWO2020178721A5 (https=) | 2023-03-13 |
| JP2022522819A5 JP2022522819A5 (https=) | 2023-03-13 |
| JP7555346B2 JP7555346B2 (ja) | 2024-09-24 |
Family
ID=69845470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551939A Active JP7555346B2 (ja) | 2019-03-02 | 2020-03-02 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 |
| JP2024155453A Pending JP2024170602A (ja) | 2019-03-02 | 2024-09-10 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155453A Pending JP2024170602A (ja) | 2019-03-02 | 2024-09-10 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220142959A1 (https=) |
| EP (2) | EP4464378A3 (https=) |
| JP (2) | JP7555346B2 (https=) |
| KR (2) | KR102941068B1 (https=) |
| CN (2) | CN119097618A (https=) |
| AU (2) | AU2020231189B2 (https=) |
| BR (1) | BR112021017203A2 (https=) |
| CA (1) | CA3131948A1 (https=) |
| DK (1) | DK3934637T3 (https=) |
| ES (1) | ES2990183T3 (https=) |
| FI (1) | FI3934637T3 (https=) |
| HR (1) | HRP20241150T1 (https=) |
| HU (1) | HUE068527T2 (https=) |
| IL (2) | IL285870B2 (https=) |
| LT (1) | LT3934637T (https=) |
| MA (1) | MA55199B1 (https=) |
| MD (1) | MD3934637T2 (https=) |
| MX (2) | MX2021010568A (https=) |
| PL (1) | PL3934637T3 (https=) |
| PT (1) | PT3934637T (https=) |
| RS (1) | RS65849B1 (https=) |
| SG (1) | SG11202109512SA (https=) |
| SI (1) | SI3934637T1 (https=) |
| SM (1) | SMT202400334T1 (https=) |
| WO (1) | WO2020178721A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) * | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| US20250025442A1 (en) * | 2020-12-10 | 2025-01-23 | Texas Tech University System | BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| WO2024243004A2 (en) * | 2023-05-19 | 2024-11-28 | The Children's Hospital Of Philadelphia | Compositions and methods for treating traumatic brain injury |
| WO2025166100A1 (en) * | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (en) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acetyl leucine for treating syngap1-related disorders |
| WO2025264957A2 (en) * | 2024-06-20 | 2025-12-26 | Intrabio Inc. | Acetyl leucine for treating neurodevelopmental disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| US20140080885A1 (en) * | 2012-09-13 | 2014-03-20 | University Of South Florida (A Florida Non-Profit Corporation) | Methods of treating traumatic brain injury |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| NZ750391A (en) | 2016-08-11 | 2026-03-27 | Intrabio Ltd | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| WO2019036442A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY |
-
2020
- 2020-03-02 WO PCT/IB2020/051767 patent/WO2020178721A1/en not_active Ceased
- 2020-03-02 SI SI202030476T patent/SI3934637T1/sl unknown
- 2020-03-02 JP JP2021551939A patent/JP7555346B2/ja active Active
- 2020-03-02 PL PL20712029.6T patent/PL3934637T3/pl unknown
- 2020-03-02 KR KR1020217031422A patent/KR102941068B1/ko active Active
- 2020-03-02 SG SG11202109512SA patent/SG11202109512SA/en unknown
- 2020-03-02 DK DK20712029.6T patent/DK3934637T3/da active
- 2020-03-02 SM SM20240334T patent/SMT202400334T1/it unknown
- 2020-03-02 HR HRP20241150TT patent/HRP20241150T1/hr unknown
- 2020-03-02 RS RS20240913A patent/RS65849B1/sr unknown
- 2020-03-02 US US17/435,784 patent/US20220142959A1/en active Pending
- 2020-03-02 CN CN202411228005.XA patent/CN119097618A/zh active Pending
- 2020-03-02 CA CA3131948A patent/CA3131948A1/en active Pending
- 2020-03-02 MA MA55199A patent/MA55199B1/fr unknown
- 2020-03-02 EP EP24188941.9A patent/EP4464378A3/en active Pending
- 2020-03-02 KR KR1020257040124A patent/KR20250171484A/ko active Pending
- 2020-03-02 IL IL285870A patent/IL285870B2/en unknown
- 2020-03-02 CN CN202080029158.5A patent/CN114040757B/zh active Active
- 2020-03-02 BR BR112021017203A patent/BR112021017203A2/pt unknown
- 2020-03-02 EP EP20712029.6A patent/EP3934637B1/en active Active
- 2020-03-02 LT LTEPPCT/IB2020/051767T patent/LT3934637T/lt unknown
- 2020-03-02 FI FIEP20712029.6T patent/FI3934637T3/fi active
- 2020-03-02 AU AU2020231189A patent/AU2020231189B2/en active Active
- 2020-03-02 MD MDE20220032T patent/MD3934637T2/ro unknown
- 2020-03-02 MX MX2021010568A patent/MX2021010568A/es unknown
- 2020-03-02 IL IL321899A patent/IL321899A/en unknown
- 2020-03-02 PT PT207120296T patent/PT3934637T/pt unknown
- 2020-03-02 HU HUE20712029A patent/HUE068527T2/hu unknown
- 2020-03-02 ES ES20712029T patent/ES2990183T3/es active Active
-
2021
- 2021-09-02 MX MX2024015063A patent/MX2024015063A/es unknown
-
2024
- 2024-09-10 JP JP2024155453A patent/JP2024170602A/ja active Pending
-
2025
- 2025-06-30 AU AU2025204995A patent/AU2025204995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Szekanecz et al. | The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout | |
| JP2023100869A5 (https=) | ||
| JP2007514750A5 (https=) | ||
| JP2023100870A5 (https=) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| CN1311628A (zh) | 治疗皮肤过敏和感染的方法和组合物 | |
| JP2007533687A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2020534270A5 (https=) | ||
| JPWO2021099783A5 (https=) | ||
| IL315023A (en) | Neuroactive steroids for treatment of cns-related disorders | |
| JPWO2020178721A5 (https=) | ||
| JP2024152860A5 (https=) | ||
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2007509876A (ja) | ペラルゴニウム種からの抽出物の使用 | |
| JPWO2022232504A5 (https=) | ||
| JPWO2022218956A5 (https=) | ||
| RU2021128588A (ru) | Лейцин, ацетиллейцин и родственные аналоги для лечения заболевания | |
| JPWO2022106711A5 (https=) | ||
| CN108371712B (zh) | 咖啡因与PPARγ激动剂联合制备AD药物中的用途 | |
| CN115279354B (zh) | 氯胺酮用于治疗恶病质的用途 | |
| JP2003535133A5 (https=) | ||
| CN104427982B (zh) | 治疗炎性和免疫障碍的组合物 | |
| JPWO2019236938A5 (https=) | ||
| CH629667A5 (fr) | Composition pharmaceutique agissant sur la motricite gastro-intestinale. |